SCHEMBL19989344

SCHEMBL19989344

Cc1cc(S(=O)(=O)N2CC[C@H](O)C2)ccc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ABL1 P00519 1/20 0.50
RIN1 Q13671 1/20 0.50
LMNA P02545 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
PIK3CD O00329 2/20 0.46
PIK3CG P48736 2/20 0.46
PIK3CB P42338 1/20 0.46
GAA P10253 2/20 0.46
HTT P42858 1/20 0.45
POLB P06746 1/20 0.45
MCOLN3 Q8TDD5 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KCNH2 Q12809 1/20 0.45
HRH3 Q9Y5N1 1/20 0.45
PKM P14618 1/20 0.44
KDM4E B2RXH2 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19989448 1.00 ALDH1A1 (0.50) ALDH1A1MEN1KMT2AABL1RIN1
SCHEMBL29859401 1.00 ALDH1A1 (0.50) ALDH1A1MEN1KMT2AABL1RIN1
SCHEMBL19989346 1.00 ALDH1A1 (0.50) ALDH1A1MEN1KMT2AABL1RIN1
SCHEMBL29859224 1.00 ALDH1A1 (0.50) ALDH1A1MEN1KMT2AABL1RIN1
SCHEMBL29859621 0.92 ABL1 (0.55) ALDH1A1MEN1KMT2AABL1RIN1
SCHEMBL19989280 0.92 ABL1 (0.55) ALDH1A1MEN1KMT2AABL1RIN1
SCHEMBL29859787 0.89 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AABL1RIN1
SCHEMBL19989508 0.89 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AABL1RIN1
SCHEMBL25896232 0.86 ALDH1A1 (0.52) ALDH1A1MEN1KMT2AABL1RIN1
SCHEMBL19989513 0.84 TDO2 (0.49) ALDH1A1GAAPOLBMCOLN3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109715608-B Indazole compounds for use in tendon and/or ligament injuries 诺华股份有限公司 2022-08-05 CN disclosed
EP-3515894-B1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2021-04-07 EP disclosed
EP-3515894-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES Novartis AG (CH) 2019-07-31 EP disclosed
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries NOVARTIS AG (CH) 2018-10-30 US disclosed
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2018-03-29 US disclosed
WO-2018055550-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries SLC10A2, MMP1, TNNI3 ALDH1A1 442/4885MEN1 2014/4885KMT2A 3008/4885
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries MMP1, SLC10A2, TNNI3 ALDH1A1 414/4885MEN1 2007/4885KMT2A 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.